Please wait while the formulary information is being retrieved.
PEGASYS (peginterferon alfa-2a)
- chronic hepatitis B
- chronic infection of genotype 1 hepatitis C virus
- chronic infection of genotype 4 hepatitis C virus
- chronic infection of genotype 2 hepatitis C virus
- chronic infection of genotype 3 hepatitis C virus
180 mcg/0.5 mL subcutaneous syringe
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly
180 mcg/mL subcutaneous solution
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly
180 mcg/mL subcutaneous solution
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly
Chronic hepatitis B
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly for 48 weeks
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly for48 weeks
Chronic hepatitis C - genotype 1
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly for 48 weeks
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly for48 weeks
Chronic hepatitis C - genotype 2
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly for 48 weeks
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly for48 weeks
Chronic hepatitis C - genotype 3
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly for 48 weeks
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly for48 weeks
Chronic hepatitis C - genotype 4
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly for 48 weeks
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly for48 weeks
Chronic hepatitis C - genotype 5
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly for 48 weeks
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly for48 weeks
Chronic hepatitis C - genotype 6
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 1 milliliter (180 mcg) by subcutaneous route once weekly for 48 weeks
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly
- Inject 0.5 milliliter (180 mcg) by subcutaneous route once weekly for48 weeks
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- telbivudine
- typhoid vaccine
- Tysabri
- Tyzeka
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Droxia
- Fazaclo
- Ferriprox
- Hydrea
- hydroxyurea
- Versacloz
Severe
Moderate
- erlotinib
- Tarceva
- Acute pancreatitis
- Autoimmune hepatitis
- Hepatic failure
Contraindicated
- Cerebrovascular accident
- Colitis
- Depression
- Diabetic retinopathy
- Hypertensive retinopathy
- Psychiatric disorder
- Retinal thrombosis
- Severe anemia
- Severe infection
- Severe neutropenic disorder
- Severe renal impairment
- Severe thrombocytopenia
- Suicidal ideation
Severe
Moderate
- Aplastic anemia
- Autoimmune disease
- Diabetes mellitus
- Hyperthyroidism
- Hypoglycemic disorder
- Hypothyroidism
- Peripheral neuropathy
- Pulmonary disease
PEGASYS (peginterferon alfa-2a)
- chronic hepatitis B
- chronic infection of genotype 1 hepatitis C virus
- chronic infection of genotype 4 hepatitis C virus
- chronic infection of genotype 2 hepatitis C virus
- chronic infection of genotype 3 hepatitis C virus
- Depression
- Fever
- Neutropenic disorder
- Abdominal pain with cramps
- Allergic dermatitis
- Alopecia
- Anorexia
- Arthralgia
- Back pain
- Concentration difficulty
- Diarrhea
- Dizziness
- Fatigue
- Flu-like symptoms
- General weakness
- Headache disorder
- Injection site sequelae
- Insomnia
- Irritability
- Myalgia
- Nausea
- Nervousness
- Pain
- Pruritus of skin
- Symptoms of anxiety
- Vomiting
- Xerostomia
More Frequent
Severe
Less Severe
- Bacterial infection
- Bacterial sepsis
- Endocarditis
- Hypothyroidism
- Lymphopenia
- Osteomyelitis
- Pneumonia
- Pyelonephritis
- Thrombocytopenic disorder
- Blurred vision
- Cough
- Dry skin
- Dyspnea
- Eczema
- Hyperhidrosis
- Memory impairment
- Mood changes
- Skin rash
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Abscess
- Acute myocardial infarction
- Anaphylaxis
- Anemia
- Angioedema
- Aplastic anemia
- Autoimmune hepatitis
- Bronchiolitis obliterans
- Bronchospastic pulmonary disease
- Cardiac arrhythmia
- Cerebrovascular accident
- Cholangitis
- Colitis
- Dehydration
- Diabetes mellitus
- Drug-induced psychosis
- Exfoliative dermatitis
- Hallucinations
- Hearing loss
- Homicidal ideation
- Hyperglycemia
- Hypertension
- Hyperthyroidism
- Hypoglycemic disorder
- Idiopathic thrombocytopenic purpura
- Infection
- Interstitial nephritis
- Interstitial pneumonitis
- Intracerebral hemorrhage
- Macular retinal edema
- Manic disorder
- Optic neuritis
- Pancreatitis
- Pancytopenia
- Papilledema
- Peptic ulcer
- Peripheral neuropathy
- Pulmonary hypertension
- Pulmonary infiltrates
- Pulmonary thromboembolism
- Pure red cell aplasia
- Purpura
- Retinal detachment
- Retinal disorder
- Retinal thrombosis
- Rheumatoid arthritis
- Sarcoidosis
- Seizure disorder
- Steatosis of liver
- Stevens-johnson syndrome
- Suicidal ideation
- Supraventricular arrhythmias
- Systemic lupus erythematosus
- Thrombosis of retinal vein
- Thrombotic thrombocytopenic purpura
- Thyroiditis
- Ulcerative colitis
- Urticaria
- Vision loss
Less Severe
- Aggressive behavior
- Angina
- Chest pain
- Chills
- Dyspepsia
- Myositis
- Psoriasis
- Tongue discoloration
Contraindicated
Peginterferon Alfa-2a
Contains benzyl alcohol; possible increased incidence of neurologic and respiratory adverse events in neonates and infants. Growth inhibition reported. Contraindicated per manufacturer.
- 1 Day – 364 Days
- 1 Contains benzyl alcohol; possible increased incidence of neurologic and respiratory adverse events in neonates and infants. Growth inhibition reported. Contraindicated per manufacturer.
Severe Precaution
Peginterferon Alfa-2a
Delays in growth reported in pediatric studies. Safety and efficacy not established age < 3 years.
- 1 Years – 3 Years
- Delays in growth reported in pediatric studies. Safety and efficacy not established age < 3 years.
Management or Monitoring Precaution
Peginterferon Alfa-2a
Monitor height and weight for impaired growth. Unknown long term effects on growth. Monitor blood counts.
- 3 Years – 18 Years
- Monitor height and weight for impaired growth. Unknown long term effects on growth. Monitor blood counts.
Peginterferon Alfa-2A
- Severity Level:
2
- Additional Notes: Insufficient human data available on developmental toxicity risk.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Peginterferon Alfa-2A
Potential for adverse effects in nursing infant
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Potential for adverse effects in nursing infant |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Peginterferon Alfa-2A
General-CNS and systemic drug effects may be more severe in the elderly. Renal-Doses should be reduced for CrCL<30mL/min. Incidence of toxic reactions may be higher if CrCL<51 mL/min. Neuro/Psych-Monitor very closely for worsening of or new onset depression.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | Y | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- This medication may rarely cause or worsen some serious medical conditions, including mental/mood problems (such as depression), autoimmune conditions (such as lupus, rheumatoid arthritis), blood vessel problems (such as heart disease), or infections. Careful monitoring by your doctor may decrease your risk. Tell your doctor right away if you develop any serious symptoms or side effects (see Side Effects section). Some side effects may go away or lessen after stopping treatment with this medication.
| Chronic hepatitis B | |
| B18.0 | Chronic viral hepatitis B with delta-agent |
| B18.1 | Chronic viral hepatitis B without delta-agent |
| Chronic hepatitis C - genotype 1 | |
| B18.2 | Chronic viral hepatitis C |
| Chronic hepatitis C - genotype 2 | |
| B18.2 | Chronic viral hepatitis C |
| Chronic hepatitis C - genotype 3 | |
| B18.2 | Chronic viral hepatitis C |
| Chronic hepatitis C - genotype 4 | |
| B18.2 | Chronic viral hepatitis C |
| 0-9 | A-Z |
|---|---|
| B18.0 | Chronic viral hepatitis B with delta-agent |
| B18.1 | Chronic viral hepatitis B without delta-agent |
| B18.2 | Chronic viral hepatitis C |
| B18.2 | Chronic viral hepatitis C |
| B18.2 | Chronic viral hepatitis C |
| B18.2 | Chronic viral hepatitis C |
Formulary Reference Tool